Glaukos (NYSE:GKOS) Director Sells $1,915,650.00 in Stock

Glaukos Corporation (NYSE:GKOS) Director Marc Stapley sold 15,000 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total transaction of $1,915,650.00. Following the sale, the director directly owned 37,449 shares in the company, valued at $4,782,611.79. This trade represents a 28.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Glaukos Stock Up 3.6%

NYSE:GKOS traded up $4.31 on Monday, hitting $124.29. 872,424 shares of the company’s stock traded hands, compared to its average volume of 736,399. The company has a market cap of $7.14 billion, a PE ratio of -80.71 and a beta of 0.67. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $161.78. The firm has a 50-day moving average price of $111.25 and a 200-day moving average price of $96.29.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The firm had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. During the same quarter in the prior year, the business posted ($0.28) earnings per share. The company’s quarterly revenue was up 38.1% compared to the same quarter last year. Equities analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GKOS. Wellington Management Group LLP boosted its holdings in Glaukos by 10.4% in the third quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock valued at $292,004,000 after acquiring an additional 336,266 shares during the last quarter. Primecap Management Co. CA lifted its stake in Glaukos by 23.3% during the third quarter. Primecap Management Co. CA now owns 2,253,788 shares of the medical instruments supplier’s stock worth $183,796,000 after purchasing an additional 425,790 shares during the last quarter. State Street Corp increased its stake in Glaukos by 5.3% in the 2nd quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock worth $215,914,000 after purchasing an additional 105,972 shares during the period. Ameriprise Financial Inc. increased its position in shares of Glaukos by 3.5% during the second quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock valued at $206,503,000 after buying an additional 68,497 shares during the period. Finally, Alliancebernstein L.P. raised its stake in Glaukos by 38.5% during the third quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier’s stock valued at $141,365,000 after buying an additional 481,620 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analysts Set New Price Targets

GKOS has been the subject of a number of recent analyst reports. UBS Group raised their price target on Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, December 23rd. Needham & Company LLC restated a “buy” rating and set a $125.00 price objective on shares of Glaukos in a research report on Wednesday, January 14th. JPMorgan Chase & Co. lifted their target price on shares of Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Stifel Nicolaus boosted their price target on shares of Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Citigroup upped their price target on Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $131.38.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.